FDA and FTC warn Nikte’s Wholesale over Delta-8 THC edibles sold as adulterated foods and child-appealing copycat snacks.
What happened
FDA and FTC reviewed the company’s websites in January, May, and June 2023 and found that customers place orders there for products represented as containing Delta-8 THC, with charges by Nikte’s Wholesale. FDA determined that four Delta-8 THC products are adulterated (contain an unsafe food additive) because Delta-8 THC is not approved for use in conventional food and is not generally recognized as safe. FTC found that the packaging and marketing imitate well-known snack brands and may appeal to children.
What FDA found
The Delta-8 THC products are adulterated because they contain Delta-8 THC, which is an unsafe food additive for use in conventional food.
FD&C Act § 402(a)(2)(C)(i), 21 U.S.C. 342(a)(2)(C)(i)The company introduced or delivered for introduction into interstate commerce adulterated food.
FD&C Act § 301(a), 21 U.S.C. 331(a)Delta-8 THC is not approved as a food additive and FDA found no basis that it is generally recognized as safe (GRAS) for conventional food.
FD&C Act §§ 201(s), 409(a), 21 U.S.C. 321(s), 348(a); 21 CFR 170.30The products are packaged and advertised in forms and with branding that look like well-known candies, chips, and drinks, which may appeal to children and mislead consumers.
FTC Act § 5, 15 U.S.C. § 45; § 12, 15 U.S.C. §§ 52, 55(a)(1)
What FDA wants
FDA tells the company to notify it in writing within 15 working days of the steps taken to address the violations, prevent recurrence, and include documentation; if corrective actions cannot be completed, the company must state why and when it will finish. FTC separately tells the company to immediately stop marketing edible Delta-8 THC products that imitate conventional foods and to notify FTC within 15 working days.
Who should pay attention
- Sellers of Delta-8 THC edibles and beverages
- Retailers and distributors of copycat THC snack products
- Packaging and labeling teams for cannabis-derived foods
This is a summary. Read the original letter on fda.gov.